Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events

Acta neurologica Belgica
Yara Dadalti Fragoso

Abstract

Fingolimod was the first oral medication approved for management of multiple sclerosis and is currently used by tens of thousands patients worldwide. Fingolimod acts via the sphingosine 1-phosphate (S1P) receptor, maintaining peripheral lymphocytes entrapped in the lymph nodes. In consequence, there is a reduction in the infiltration of aggressive lymphocytes into the central nervous system. The drug is safe and effective, and its first hours of use are associated with related to S1P receptors in the heart. This side effect is well known by all doctors prescribing fingolimod. However, the drug has other potential adverse events that, although relatively rare, require awareness from the neurologist. Among these there are infections (herpes simplex, herpes zoster, Cryptococcus, Epstein-Barr virus, hepatitis, Molluscum Contagiosum, and leishmaniosis), lung and thyroid complications, refractory headaches, encephalopathy, vasculopathy, tumefactive lesions in magnetic resonance imaging and ophthalmological disorders. The present review lists the non-cardiologic adverse events that all neurologists prescribing fingolimod should be aware of.

References

Jan 22, 2010·The New England Journal of Medicine·Ludwig KapposUNKNOWN FREEDOMS Study Group
Jan 22, 2010·The New England Journal of Medicine·Jeffrey A CohenUNKNOWN TRANSFORMS Study Group
Mar 16, 2011·Neurology·Antonio UccelliMatteo Bassetti
Aug 10, 2011·Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society·Roberto Gallego-PinazoManuel Díaz-Llopis
Mar 1, 2012·Neurology·Nieraj Jain, M Tariq Bhatti
Jul 4, 2012·Archives of Neurology·Ernst-Wilhelm RadueUNKNOWN FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group
Oct 5, 2012·Neurology·Femke VisserBob W van Oosten
Oct 27, 2012·Multiple Sclerosis : Clinical and Laboratory Research·Sebastian JanderHans-Peter Hartung
Nov 24, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Emerson Y ChenWilliam M Lee
Jan 12, 2013·JAMA Ophthalmology·Armin R AfsharSeenu M Hariprasad
Jul 13, 2013·Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society·M Tariq BhattiTamer H Mahmoud
Jul 24, 2013·Neurology·Michael O Kinney, Gavin McDonnell
May 29, 2014·Multiple Sclerosis : Clinical and Laboratory Research·J A van RossumJ Killestein
Jun 18, 2014·Expert Opinion on Drug Safety·Melanie D WardMyla D Goldman
Jun 25, 2014·Enfermedades infecciosas y microbiología clínica·Michal Maciej KawiorskiIñigo Corral
Jul 9, 2014·Journal of the Neurological Sciences·M A HellmannI Steiner
Jul 24, 2014·Patient Preference and Adherence·Chiara ZeccaClaudio Gobbi
Oct 17, 2014·BMJ Case Reports·R AlroughaniA Thussu
Oct 24, 2014·Neurology. Neuroimmunology and Neuroinflammation·Vivien LiHelmut Butzkueven
Nov 30, 2014·Multiple Sclerosis : Clinical and Laboratory Research·A K ArtemiadisI Papanastasiou
Dec 11, 2014·Journal of the Neurological Sciences·J FloresT Corona
Jul 1, 2013·Multiple Sclerosis and Related Disorders·Roy G BeranDennis J Cordato
Jul 1, 2013·Multiple Sclerosis and Related Disorders·Oscar Jim Michael CoppesJacqueline Bernard
May 21, 2015·Arquivos de neuro-psiquiatria·Yara Dadalti Fragoso, Joseph Bruno Bidin Brooks
Jun 15, 2015·Acta neurologica Belgica·Sabina BoangherPascal Mespouille
Sep 9, 2015·Multiple Sclerosis and Related Disorders·M H HarirchianB Siroos
Sep 10, 2015·Mayo Clinic Proceedings·Margherita RussoRocco Salvatore Calabrò
Oct 13, 2015·JAMA Neurology·Lutz AchtnichtsKrassen Nedeltchev
Nov 12, 2015·Therapeutic Advances in Neurological Disorders·Simon FaissnerGisa Ellrichmann
Jan 12, 2016·JAMA Neurology·Amy K ForrestelRobert G Micheletti

❮ Previous
Next ❯

Citations

Feb 26, 2020·Expert Opinion on Biological Therapy·Marjorie ArgolloSilvio Danese
Feb 28, 2020·Clinical Neuropharmacology·Hussein AlgahtaniIbraheem Meftah
Jan 4, 2020·CNS Drugs·Damiano PaolicelliMaria Trojano
Sep 23, 2020·The American Journal of Tropical Medicine and Hygiene·Eloise WilliamsJason C Kwong
Mar 6, 2021·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Juan S LasaLaurent Peyrin-Biroulet
Sep 30, 2021·The New England Journal of Medicine·William J SandbornUNKNOWN True North Study Group
Jan 5, 2022·Journal of Neurology·Tjalf ZiemssenUNKNOWN PANGAEA study group

❮ Previous
Next ❯

Methods Mentioned

BETA
contraception

Related Concepts

Related Feeds

Basal Ganglia Cerebrovascular Disease

Basal ganglia cerebrovascular disease is a condition where the blood vessels in the basal ganglia are damaged or malfunction. Discover the latest research on basal ganglia cerebrovascular disease here.

CNS Lymphatics

The CNS contains lymphatic vessels in the meninges that connect and drain the CSF into the peripheral lymphatic system. Impaired functioning of the CNS lymphatic system can be dangerous with the accumulation of toxic substances such as amyloid protein that is part of Alzheimer’s disease pathogenesis. Here is the latest research on the CNS lymphatics.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.